Cambridge ’s Acceleron, Celgene say blood disorder drug meets mark in trial

Cambridge-based Acceleron Pharma and partner Celgene Corp. said Monday they plan to seek FDA approval for a blood disorder treatment next year after a successful late-stage study. Celgene (Nasdaq: CELG) and Acceleron (Nasdaq: XLRN) announced positive results from the Phase 3 trial of luspatercept, a treatment for beta-thalassemia patients who are dependent on blood transfusions. According to the companies, the drug helped red blood cells mature in these adult patients, and reduced the burden of…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news